Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

To join this study, you must be an adult aged 18 or older and have a confirmed diagnosis of mantle cell lymphoma. Your lymphoma must have either come back or not responded to previous treatments. You must also have already received certain standard treatments, including specific types of immunotherapy and at least two different Bruton's Tyrosine Kinase (BTK) inhibitor medications.

Additionally, your lymphoma needs to be 'measurable,' meaning doctors can see and track it, for example, on scans. They'll also need a sample of your lymphoma tissue, either an old one or you might need a new small procedure to get one. You should be generally well enough to take part in a study like this, as assessed by a doctor, and have healthy organ function.

There are also some reasons why you might not be able to join. For example, if your lymphoma has spread to your brain or spinal cord, or if you've had certain other cancers recently. If you've previously taken a similar type of drug to BGB-11417 (called a BCL-2 inhibitor), or had certain stem cell or CAR T-cell treatments recently, you also can't participate. Other reasons include significant heart problems, recent major surgery, or an active infection requiring strong medication.

If you decide to take part in this study, you will be given the study drug, BGB-11417. Initially, the drug might be given with a slow increase in dose over time to see how you tolerate it. You will have regular visits to the clinic so doctors can monitor your health, check for side effects, and see how the treatment is working. These visits will likely involve physical exams, blood tests, and scans to assess your lymphoma. The total duration of your participation will depend on how you respond to the treatment and the study's specific design, but it will involve ongoing assessments and follow-up.